Australia's most trusted
source of pharma news
Friday, 17 October 2025
Posted 17 October 2025 AM
It looks like Eli Lilly will win the race to bring an oral form of a weight loss blockbuster to Australia.
Following the announcement of positive top-line results from its ACHIEVE clinical trial program, Lilly plans to submit orforglipron in oral form to the TGA for the treatment of both type 2 diabetes and obesity by the end of the year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.